Rather than viewing Crizotinib only as a member of the alk/ros1/met inhibitor class, its clinical role is better understood through the indications recorded here. ALK-positive metastatic NSCLC; ROS1-positive metastatic NSCLC; selected ALK-positive anaplastic large-cell lymphoma and other label-specific tumors is the principal oncology use described in the database. Inhibits ALK, ROS1 and MET tyrosine kinases. The treatment depends on identifying the relevant oncogenic kinase alteration rather than selecting therapy from tumor site alone. The treatment is classified as Targeted Therapy; Tyrosine Kinase Inhibitor and is associated with NSCLC; ALCL. Regimens listed include Crizotinib monotherapy. These examples show where the medicine is incorporated into treatment pathways and, where relevant, which agents accompany it. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Selection should remain anchored to the specific disease context, including any biomarker, receptor, stage, or previous-treatment criterion supplied with the indication. The pharmacologic mechanism provides context but does not by itself establish eligibility. This database entry is intended for clinical reference and not for individualized prescribing, dose selection, or treatment planning. Current product labeling and relevant guideline versions should be used to verify contemporary practice.